Editorial

Death of the Great Laboratory of Clinical Medical Science

Free-market capitalism has brought unimaginable innovations to mankind in the last 200 years, more so than any other economic...

Clinical Updates Confirming Advances and Meaningful Benefits for Patients

Earlier this year, during the meetings of the American Association for Cancer Research (AACR), held April 16-20 in New...

Can the President Still Cure Cancer?

Forty- five years ago, in a room filled with congressional members from both sides of the isle, distinguished guests,...

Early Detection: The New Cancer Paradigm

A seemingly healthy patient walks into the doctor’s office for a routine checkup. The doctor says: "I have good...

Contract Manufacturing of Antibody-drug Conjugates – A Growing Market

The demand for manufacturing capacity of antibody-drug conjugates (ADCs), which includes a highly potent cytotoxic drug linked to a monoclonal...

Developing the Next Generation of Clinically Successful Antibody-drug Conjugates

Since the approval of the first antibody-drug conjugate or ADC, now more than 15 years ago, scientists and researchers...

Brentuximab Vedotin Identified as Potentially Transformational in Hodgkin’s lymphoma Treament

Earlier this month, during the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), held in...
Featured Image: Ado-trastuzumab emtansine (Kadcyla; Genentech/Roche), also known as T-DM1. Courtesy: Genentech/Roche.

The Challenge of Antibody-drug Conjugates (ADC) Characterization

Therapeutic antibody–drug conjugates or ADCs (also known as immunoconjugates) selectively kill tumor cells that overexpress a specific target antigen...

How Personalization Will Improve Healthcare

While healthcare reform has many challenges, there are some very positive things happening behind the scenes. One of them...

CPhI Worldwide 2015, Antibody-drug Conjugates and Market Progression

Ahead of CPhI Worldwide 2015, CPhI expert panelist, Vivek Sharma, CEO of Pharma Solutions at Piramal, analyses the challenges...